Neoadjuvant therapy for resectable pancreatic cancer. Surg Oncol Clin N Am 2004 Oct;13(4):639-61, ix
Date
09/08/2004Pubmed ID
15350939DOI
10.1016/j.soc.2004.06.007Scopus ID
2-s2.0-4444325559 (requires institutional sign-in at Scopus site) 55 CitationsAbstract
The length and quality of life of patients with localized pancreatic cancer will be maximized by accurate preoperative assessment of resectability, a standardized technique of tumor resection, and the routine use of protocol-based adjuvant or neoadjuvant therapy. Continued efforts to enroll patients with localized and advanced pancreatic cancer into well-designed clinical trials should remain a high priority for oncologists across all disciplines. At present, preoperative therapy remains investigational but has a sound clinical basis and remains a reasonable alternative to up front surgery. Future clinical trials for resectable pancreatic cancer will lead to progress only if the principles of multidisciplinary cancer care and quality assurance are incorporated into their design and conduct.
Author List
Raut CP, Evans DB, Crane CH, Pisters PW, Wolff RAAuthor
Douglas B. Evans MD Chair, Professor in the Surgery department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdenocarcinomaAdult
Aged
Antineoplastic Combined Chemotherapy Protocols
Chemotherapy, Adjuvant
Female
Humans
Male
Middle Aged
Neoadjuvant Therapy
Neoplasm Staging
Pancreatectomy
Pancreatic Neoplasms
Prognosis
Radiotherapy Dosage
Radiotherapy, Adjuvant
Randomized Controlled Trials as Topic
Risk Assessment
Survival Analysis
Treatment Outcome
United States
